Introduction
Tumor necrosis factor a (TNF) is a proinflammatory cytokine that has a critical role in the pathogenesis of chronic inflammatory autoimmune diseases such as rheumatoid arthritis (RA). 1 Accordingly, TNF antagonists have proven to be effective for the treatment of RA. 2, 3 Blockade of TNF reduces the acute phase response and decreases both local and systemic levels of inflammatory mediators in patients with RA (reviewed in Tracey et al. 4 ). However, the improvement varies between patients, and approximately 30% of RA patients fail to respond to this therapy. Clinical studies revealed that the response to treatment ranges from an almost complete remission to even worsening of clinical symptoms.
The variation in the primary clinical response to treatment suggests that different effector pathways contribute to disease activity between patients. This could be the consequence of the existence of parallel pathways in a single patient whereby the relative contribution of TNF-independent effector pathways varies between patients, irrespective of the level of available TNF-bioactivity. Alternatively, the variation in response to treatment could be explained by differences in bioactive TNF levels. In this model, a good response is related to the presence and a failure to respond to the absence of bioactive TNF. The latter model is supported by the observation that indirectly measured levels of TNF-bioactivity were predictive of clinical response to TNF-blockade. 5 In addition, pre-treatment expression levels of TNF in synovial tissue are higher in responders compared with non-responders. 6 This would implicate that the failure to respond is associated with the presence of a TNF-independent pathway with concomitant lack of a TNF-pathway.
In normal physiology TNF achieves its biological effects by binding to multi-subunit receptor TNFR1 (p50) or TNFR2 (p75) on the cell surface. Soluble TNF binds with higher affinity to TNFR1 7 while transmembrane TNF primarily signals through TNFR2. 8 Although TNFR1-mediated signaling is well known for its pro-inflammatory and apoptosis-inducing capacities, the signaling through TNFR2 is less well understood. Moreover, transmembrane TNF by itself may lead to intracellular signaling, 9 making the TNF-induced signaling program even more complex. Ultimately, the signaling cascade leads to transcriptional activation of TNFresponsive genes. Similarly, the capacity of TNF-specific blockers to modulate gene expression can be considered as the qualitative and quantitative measure of the inhibition of TNF bioactivity. Thus, analyzing changes in gene transcripts after adding or deleting a certain mediator of the immune response reflects the transcriptional response to that mediator.
With the aid of genomics technology, we are now in a position to determine the genome-wide pharmacological outcome of TNF-blockade in RA patients. We hypothesize that an in-depth understanding of the transcriptional changes after TNF-blockade in RA will allow us to evaluate the presence and/or absence of TNF-induced pathways at the individual patient level. Therefore, we measured the pharmacological effect of TNF-blockade in RA patients using large-scale gene expression profiling of peripheral blood (PB) cells.
Results

Pharmacogenomic response to infliximab treatment
The bioactivity of TNF in RA patients can be measured retrospectively by analyzing the change in gene transcription after TNF-blockade. Therefore, PB gene expression profiles of 15 RA patients before (t ¼ 0) and 1 month after (t ¼ 1) TNF-blocking therapy (infliximab) were compared. Using a false discovery rate of o5% significance analysis of microarray revealed 1623 significantly regulated genes: 692 genes were significantly upregulated whereas 931 genes were significantly downregulated after 1 month of treatment (for total gene list see Supplementary Table S1 ). Accordingly, these genes encompass the pharmacogenomic anti-TNF response signature and are referred to as such in this article.
The most significantly downregulated gene was peptidase inhibitor 3/SKALP, which expression level was downregulated 1.84-fold after treatment. This significant downregulation was confirmed by quantitative real-time PCR in an independent validation cohort of 18 RA patients receiving infliximab treatment (P ¼ 0.02; data not shown). To verify that the gene expression changes were indeed regulated by TNF-blockade, two different gene sets involved in TNFR1 and TNFR2 signaling were obtained (http://www.biocarta.com). For all genes in both gene sets the average value in expression level for each patient was calculated and pre-treatment levels were compared with post-treatment levels. This analysis revealed a significant downregulation of both gene sets after TNF-blockade (paired t-test Po0.05, data not shown) confirming that both TNFR signaling pathways are affected by infliximab.
To unravel the biological function of the pharmacogenomic anti-TNF response signature, we applied PANTHERs (protein analysis through evolutionary relationships) classification analysis. The downregulated genes could be classified into several biological pathways such as inflammation, angiogenesis, and B-and T-cell activation ( Table 1 ), indicating that blocking TNF dampens these immune-related pathways. The upregulated genes consisted of many genes with unknown function and could therefore not be classified into pathways.
Collectively, these data show the existence of a pharmacogenomic anti-TNF response signature as a result of blockade on TNF bioactivity.
Pharmacogenomic anti-TNF response signature is common in all patients
The identification of a pharmacogenomic anti-TNF response signature allows evaluation of the presence or absence of such a response for each individual patient. This knowledge will provide information regarding the presence or absence of TNF bioactivity before the start of treatment. Therefore, we calculated for each patient the treatment-induced change (ratio T ¼ 1/T ¼ 0) in transcript level for each gene in the pharmacogenomic anti-TNF response signature and visualized the response values between patients using supervised one-way hierarchical cluster analysis (Figure 1a ). This analysis revealed significant changes in the expression level of the pharmacogenomic anti-TNF response signature in all RA patients tested. Thus, all patients carry features of TNF bioactivity irrespective of clinical response. 
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However, this analysis does not give much information regarding the possible inter-individual difference in the magnitude of pharmacological response. Hence, for each individual patient a mean expression value for both the up-and downregulated pharmacogenomic response genes was calculated and pre-treatment values were compared with post-treatment values (Figure 1b) . These results revealed that all patients treated showed a similar magnitude of the pharmacogenomic anti-TNF response signature.
Next, we wanted to analyze if inter-individual differences present at baseline or after treatment may be related to clinical response to treatment. Therefore, for each clinical response group (poor, moderate and good responders using EULAR criteria) the average expression levels for both the up-and downregulated pharmacogenomic anti-TNF response genes were calculated and the different response groups were compared with each other (Figure 1c ). Baseline expression levels, pharmacological change as well as remaining expression levels for the genes encompassing the above described pharmacogenomic anti-TNF response signature were similar between the different clinical response groups. Collectively, these data could not reveal consistent differences in the pharmacogenomic anti-TNF response signature genes between clinical responders and non-responders.
These results imply that all RA patients have a certain level of the active TNF response program before treatment, which is reflected by a common pharmacological response toward TNF-blockade irrespective to clinical response to treatment.
Heterogeneity in pharmacological anti-TNF response
Although all patients showed a common pharmacogenomic response, not all patients showed a good clinical response to treatment. This suggests that other pathways might contribute to disease, which may include pathways that are differentially affected by TNF-blockade therapy. To examine the existence of subtle interindividual differences in the pharmacodynamic (PD)   B145  B125  B128  B153  B157  B149  B142  B129  B140  B143  B130  B159  B154  B160 anti-TNF response, we searched for differences between the pharmacological anti-TNF responses at the individual patient level by calculating for each patient and for each gene the ratio of gene expression pre-vs posttherapy (log-2 ratios). This allowed us to search for gene expression differences that are missed in the group (postvs pre-treatment)-based comparison. A total of 440 genes that showed at least a twofold change after treatment in at least four patients were found. Unsupervised two-way hierarchical clustering based on the expression levels of these 440 genes divided the RA patients into two different patient groups (I and II) ( 
I.
II.
b Figure 2 Inter-individual differences in treatment-induced changes in gene expression. Gene expression ratio's (biological response) that differed at least twofold after treatment in at least four patients were two-way hierarchically clustered. The resulting 440 genes divided the RA patients into two different patient groups (I and II) based on their difference in pharmacological response (a). Significance analysis of microarray (SAM) revealed 2777 significantly (false discovery rate (FDR)o5%) differential changed genes between groups I and II. Cluster analysis was used to visualize these significant pharmacological differences in gene expression changes and PANTHER classification analysis was applied to determine the biological relevance of the pharmacological differences (b). Upregulated genes after therapy are indicated by a red color, downregulated by a green color and genes that show no differences in expression after therapy are indicated in black. At the top the EULAR response is given in colors: Red, 0 ¼ poor response; blue, 1 ¼ moderate response; green, 2 ¼ good response.
for the robustness of this cluster-based sub-classification of patients (data not shown). Significance analysis of microarray on all the measured genes revealed 249 genes that were increased and 2528 genes that were decreased in group II (false discovery rateo5%; Figure 2b ). PANTHER classification analysis revealed that the upregulated 2528 genes in group I are involved in processes such as oxidative phosphorylation, DNA repair, (pro-) apoptosis, protein metabolism, modification and biosynthesis, whereas 249 genes upregulated in group II are involved in (anti-)apoptosis, cell proliferation and cell differentiation. These analyses performed at the individual patient level show heterogeneity in the biological processes that are activated as a result of treatment. The observed variation in the pharmacological response might help to understand (part) of the mechanism explaining the differential clinical responsiveness to TNF-blockade.
Discussion
This study shows the pharmacological effect of TNFblockade on the PB transcriptome profile. Four weeks after the start of TNF-blockade, significant changes in the expression levels were found. Pathway level analysis of the significantly differential expressed genes revealed an overall dampening of immune response after TNFblockade. According to the pro-inflammatory cytokine activity of TNF, we observed a downregulation of genes involved in inflammation, angiogenesis, T-and B-cell activation after TNF-blocking therapy. Interestingly, we observed this down-modulation of inflammation in every treated RA patient irrespective of clinical response, implying that all RA patients had an active TNF response program before treatment.
Good PD markers are needed to improve the prediction of drug efficacy and safety at the individual patient level. These quantitative PD markers should reflect features of drug exposure and drug response with respect to modulation of the molecular target, the cognate biochemical pathways and/or downstream biological effects. 10, 11 The availability of these quantitative PD markers may provide a rational basis for decision making during, for example, treatment optimization. A relatively easy to measure PD marker currently described for TNF-blocking therapy is serum C-reactive protein levels. 2 In addition, cytokine levels for interleukin-1RA and interleukin-6 are described to be downregulated early after TNF-blockade and the change in interleukin-6 levels is associated with C-reactive protein reduction. 12 However, most of the described PD markers are assessed by using mean levels of patient groups and therefore do not necessarily apply for each individual patient. Our findings show a significant downregulation of several pro-inflammatory genes after 1 month of infliximab treatment in all treated patients, irrespective of clinical response, indicating that these genes are treatment specific. Therefore, this anti-TNF response signature provides a rich framework for selecting PD markers potentially useful for monitoring the pharmacological response of TNF-blockade therapy. Especially gene targets, such as the most significantly downregulated gene SKALP, may be selected as possible PD marker to monitor anti-TNF response. Although we observed an age difference between the test and validation group, we did not consider the difference relevant for the pharmacological response. Studying the kinetics of these genes and their products should reveal if they can also be used as early PD markers.
In spite of the highly beneficial effects of TNF-blockade in suppressing disease, clinical improvement appears to approximately two-thirds of patients. Clinical studies revealed that the response to treatment ranges from an almost complete remission to even worsening of clinical symptoms. The few pharmacogenomics studies published so far were conducted to find genes predictive for clinical response to TNF-blocking therapy. [13] [14] [15] [16] [17] Overall, the identification of predictive biomarkers for clinical response to treatment has not yet led to consistent results, although synovial TNF expression may explain approximately 10% of the effect. 6 As indicated by the small sample size per clinical response group, this study was not designed to identify predictors of clinical response to treatment. In contrast to the predictive studies, this study was performed to determine the pharmacological response in PB induced by TNF-blocking therapy. Our results provide evidence for the concept that all treated patients reveal a comparable qualitative and quantitative pharmacological response on TNFblockade, indicative for the neutralization of bioactive TNF irrespective of clinical response. These findings would reject the model wherein the PD response is restricted to patients who show a good clinical response (Figure 3, model A) . Instead, our results favor a model of parallel TNF-dependent and TNF-independent pathways in the individual patient, wherein the relative contribution of the TNF-independent pathways varies between patients and may determine the clinical outcome (Figure 3, model B) . Candidates for TNF-independent pathways involve cells and mediators such as interleukin-17, B cells and T cells that have been shown to have major roles in the pathogenesis of RA. 18 Clinical response to TNF-blockade may be determined by the contribution of the TNF-independent pathway(s) to disease. If the TNF pathway is dominant over the others, patients are more likely to elicit clinical improvement after TNF-blockade. 6, 19 Conversely, when besides TNF other pathways have a major role in disease, patients will show no or minor improvement of disease activity. Further studies to reveal the identity of the TNFindependent pathways are needed. Comparative analysis between anti-TNF and other biologic-induced gene expression differences might reveal common and biologic-specific pharmacological denominators.
The overall presence of an activated TNF-pathway in all treated RA patients is in line with a study showing joint protection and changes in inflammatory markers by infliximab plus methotrexate treatment even in patients without clinical improvement, 20 although the interpretation of this study has been questioned by others. 21, 22 In addition, our results are complementary to previous work showing that a reduction of TNF mRNA levels in whole blood did not predict clinical response in RA patients treated with infliximab. 23 In spite of the presence of an active TNF response program in all RA patients treated, not all patients responded well to infliximab treatment suggesting that infliximab induced changes in other gene transcripts may differ between patients. Indeed, a detailed analysis
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LGM van Baarsen et al revealed the existence of subtle interindividual differences in the PD response that separated RA patients in two groups. Moreover, starting from a hypothesis-driven approach, we identified differential effects in the activation of interferon-response genes on blockade of TNF. 24 Further studies with larger sample sizes are needed to analyze the relation between the identified different PD response patterns and the primary clinical response to treatment. Current knowledge revealed that there are essentially two phases of unresponsiveness: a mechanistic phase directly after the start of treatment, and a secondary phase that develops in initial responders during the course of therapy. 25 As a consequence, unresponsiveness may also be explained by the formation of anti-drug antibodies ( ¼ anti-anti-TNF antibodies) in a subset of patients. Owing to the temporal aspects related to monitoring the clinical response, we cannot formally exclude the possibility that research findings from studies on the mechanistic phase of unresponsiveness might be intimately linked to processes that are (also) related to anti-drug development.
Materials and methods
Patients
In all, 33 consecutive patients with RA according to the ACR criteria were enrolled in the study from the outpatient clinic of the Academic Medical Center in Amsterdam over a period of 1 year. Inclusion criteria were: 18-85 years of age, a failure to respond to at least two disease modifying anti-rheumatic drugs including methotrexate, and active disease (defined as having a disease activity score evaluated in 28 joints (DAS28) X3.2). Patients with a history of an acute inflammatory joint disease of different origin or previous use of a TNFblocking agent were excluded. Patients were on maximal tolerable methotrexate treatment (5-30 mg per week), which had to be stable for at least 4 weeks before baseline. Oral corticosteroids (maximum dose ofp10 mg per day) and non-steroidal anti-inflammatory drug were allowed if stable for at least 1 month before baseline. Prednisone therapy p10 mg per day was allowed provided that the dosage has been stable for at least 2 months before entry. In general, patients continued their regular treatment in the same dosage, which did not change in the first month after TNF-blockade. Whole blood samples (2.5 ml) were obtained using PAXgene tubes (PreAnalytix, GmbH, Germany) from 33 RA patients before initiation of TNF-blocking therapy with infliximab (3 mg kg -1 intravenously, giving according to the usual dosing schedule for RA at baseline, at week 2, 6 and subsequently every 8 weeks). A second PAXgene tube was obtained after 1 month of treatment. All patients gave written informed consent and the study protocol was approved by the medical ethics committee (Academic Medical Center). Gene expression profiles were determined from 15 randomly chosen patients out of the 33 patients. The remaining 18 patients were used as a validation group to confirm gene expression levels by quantitative real-time PCR. An overview of the patients' characteristics is given in Table 2 . After 16 weeks of treatment, the clinical response to treatment was assessed using both the EULAR criteria 26, 27 as well as the reduction in 28-joint disease activity score of at least 1.2.
28
Blood sampling for RNA isolation Blood (2.5 ml) was drawn in PAXgene blood RNA isolation tubes (PreAnalytix) and stored at À20 1C. RNA was isolated using the PAXgene RNA isolation kit according to the manufacturer's instructions including a DNAse (Qiagen, Venlo, The Netherlands) step to remove genomic DNA. Quantity and purity of the RNA was tested using the Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA).
Sample hybridization for microarray analysis
We used 43K complementary DNA microarrays from the Stanford Functional Genomics Facility (http://microarray. org/sfgf/) printed on aminosilane-coated slides containing 
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LGM van Baarsen et al B20 000 unique genes. Only one batch of arrays was used for all experiments. First DNA spots were ultraviolet cross-linked to the slide using 150-300 mJ. Sample preparation and microarray hybridization were performed as described previously. 29, 30 Microarray data analysis Data storage and filtering was performed using the Stanford Microarray Database 31 (http://genome-www5. stanford.edu//) as described previously. 32 Raw (log2) data can be downloaded from the publicly accessible Stanford database website. To determine the significant pharmacological response to treatment, we performed a paired analysis using significance analysis of microarrays. 33 A gene was considered as significantly differential expressed if the false discovery rate was equal to or o5%. Cluster analysis 34 was used to define clusters of co-coordinately changed genes after which the data were visualized using Treeview (http://rana.lbl.gov/ EisenSoftware.htm). To interpret our data after significance analysis of microarray analysis, we applied PANTHER Classification System (Applied Biosystems, Foster City, CA, USA) at http://PANTHER.appliedbiosystem.com. 35, 36 This analysis uses the binomial statistics tool to compare the list of significantly up-or downregulated genes to a reference list (NCBI Homo sapiens) to statistically determine over-or underrepresentation of PANTHER classification categories such as biological processes. A Bonferroni correction was applied to correct for multiple testing and after classification analysis a significant P-value (Po0.05) indicates that a given category may be of biological interest.
Real-time PCR
In 48-wells PCR plates (Greiner Bio-One GmbH, Frickenhausen, Germany) 0.5 mg of total RNA was reverse transcribed into complementary DNA using the Revertaid H-minus complementary DNA synthesis kit (MBI Fermentas, St Leon-Rot, Germany) according to the manufacturer's instructions. Quantitative real-time PCR was performed using an ABI Prism 7900HT Sequence detection system (Applied Biosystems) using SybrGreen (Applied Biosystems). Primers were designed using Primer Express software and guidelines (Applied Biosystems). To calculate arbitrary values of mRNA levels and to correct for differences in primer efficiencies a standard curve was constructed. Expression levels of target genes were expressed relative to 18S RNA.
Statistical analysis
Pre-and post-treatment values were compared by paired t-test analysis using Graphpad Prism 4 (Graphpad Software, Inc., La Jolla, CA, USA) Differences were considered statistically significant with P-values o0.05.
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